Recce Pharmaceuticals

Corporate Governance

Why Invest

News and Media

Announcements

Titillium Web

Recce's Entitlement Offer is now live! Visit the page for instructions on how to participate

Recce Pharmaceuticals Ltd (ASX:RCE) has announced a A$15.8 million capital raising through a A$5.0 million placement with an Australian-based private investor and a A$10.8 million entitlement offer at the same price. The funds will primarily support Phase III topical clinical trials in Indonesia and Australia, with potential revenue expected in 2026. Directors plan to participate in the entitlement offer. The proceeds will drive Phase III trials and other development programs, ensuring a strong cash position post-raising.

The offer price of A$0.28 per new share represents discounts to recent share prices. Investors can participate in the entitlement offer from 22 April to 5 May 2025. The company expects additional R&D rebates and non-dilutive capital following the capital raising. CEO James Graham and Chairman Dr. John Prendergast expressed confidence in the company’s value and potential impact on patient outcomes.

Shareholders should refer to the offer booklet for details and contact the share registry for inquiries. The indicative timetable outlines key dates related to the placement and entitlement offer.

Recce Pharmaceuticals Ltd (ASX:RCE) has announced a A$15.8 million capital raising through a A$5.0 million placement with an Australian-based private investor and a A$10.8 million entitlement offer at the same price. The funds will primarily support Phase III topical clinical trials in Indonesia and Australia, with potential revenue expected in 2026. Directors plan to participate in the entitlement offer. The proceeds will drive Phase III trials and other development programs, ensuring a strong cash position post-raising.<br/><br/>The offer price of A$0.28 per new share represents discounts to recent share prices. Investors can participate in the entitlement offer from 22 April to 5 May 2025. The company expects additional R&D rebates and non-dilutive capital following the capital raising. CEO James Graham and Chairman Dr. John Prendergast expressed confidence in the company’s value and potential impact on patient outcomes.<br/><br/>Shareholders should refer to the offer booklet for details and contact the share registry for inquiries. The indicative timetable outlines key dates related to the placement and entitlement offer. The announcement reflects Recce’s commitment to developing synthetic anti-infectives to combat antibiotic-resistant superbugs, with recognition from WHO and FDA for its innovative approach. Investors are encouraged to engage with the company regarding this significant capital raising initiative.

Placement and Entitlement Offer to Fund Phase III Trials

Announcement summary